RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

After having been jerked around repeatedly in the partnering process, and reaching a point where their capitalization leads them to loose leverage, and having established a perfectly viable ADHD trial protocol, I really have to wonder why corx management is deferring to a potential partner.

On the up-side, it could be that the counterparty wants to inlicence the compound for all indications, and awaits the SA data before moving forward with their offer. This begs two questions: 1. why hold up the IND filing since the ADHD experimental paradigm is fine anyway (how many ways are there to skin this cat)? 2. Why not get the SA trial done, once and for all? If the data are in the can, what's holding it up (n=20, yes/no question)?

On the downside, there may be a problem with the compound for ADHD. The longer this drags on, the more I believe this. The fact that corx management says the compound is problem-free doesn't reassure me. Stoll said the exact same thing about cx-717.

Similarly, the longer this drags on, the more I suspect that the SA data are negative. If you have a robust effect, the statistics are simple. If you're digging around for a trend, the statistics get complicated and time-consuming.

For once, management should be held to their deadline. If they said end of October, it should be end of October. Such a precise date is only plausible if the data are in the can, and all that's left is the analysis. If they were still rooting around London looking for people who snore, they shouldn't have said anything.